The objectives of the present study were to utilize the deeply phenotyped and large longitudinal observational cohorts from the Parkinson’s Progression Markers Initiative (PPMI) to extend our previous studies20 and assess: (a) effects of LRRK2 and GBA1 pathogenic variants on baseline urinary BMP levels in PD manifesting and non-manifesting carriers (NMC), (b) longitudinal changes in BMP levels in LRRK2 carriers, and (c) whether baseline BMP levels predict disease progression in LRRK2, GBA1 or sPD cohorts. The gene discussed is GBA1; the disease is Parkinson disease.